PPARγ agonist rosiglitazone prevents perinatal nicotine exposure-induced asthma in rat offspring

Jie Liu, Reiko Sakurai, E. M. O’Roark, Nicholas J. Kenyon, John S. Torday, and Virender K. Rehan

Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, and Department of Medicine, University of California Davis, Davis, California

Submitted 21 September 2010; accepted in final form 16 January 2011


There is strong epidemiological and experimental evidence that perinatal exposure to maternal smoking results in detrimental long-term effects on lung growth and function, including significant suppression of alveolarization and increased predisposition to asthma in the offspring (2, 4–6, 9, 13–15, 17, 27, 30, 42, 44, 45, 49). Since the mechanisms underlying these adverse pulmonary effects remain incompletely understood, there are no effective preventive or therapeutic interventions. Recently, on the basis of in vitro and in vivo studies from our laboratory, we suggested that downregulation of homeostatic lung mesenchymal peroxisome proliferator-activated receptor-γ (PPARγ) signaling might be a key contributor to chronic lung diseases such as bronchopulmonary dysplasia and asthma (23, 34, 36, 37, 48). We previously showed that in vitro and in vivo nicotine exposures result in the downregulation of pulmonary mesenchymal PPARγ and the upregulation of myogenic signaling pathways, triggering the transdifferentiation of lipid-rich alveolar interstitial fibroblasts to myofibroblasts (23, 36, 37). Furthermore, by upregulating PPARγ signaling in vitro, nicotine-induced transdifferentiation of alveolar interstitial fibroblasts to myofibroblasts can be blocked. However, the relevance of these findings to perinatal nicotine exposure-induced asthma in offspring and whether it can be prevented by PPARγ agonists is not known. Here, using a rat model, we show that perinatal nicotine exposure alters proximal and distal airway molecular and functional phenotypes, consistent with smoke-induced asthma, and that these changes can be effectively blocked by the concomitant systemic administration of a PPARγ agonist, rosiglitazone (RGZ).

MATERIAL AND METHODS

Animals. Time-mated first-time-pregnant, pair-fed Sprague-Dawley rat dams (200–250 g body wt) received placebo (diluent, n = 16), nicotine (1 mg/kg sc, n = 16), or nicotine (1 mg/kg sc) + RGZ (3 mg/kg ip, n = 16) in 100-μl volumes daily from embryonic day 6 to postnatal day 21. After spontaneous delivery at full term, the pups were allowed to breast feed ad libitum. At postnatal day 21, the pups were killed, and the lungs and tracheas were collected for determination of relevant protein levels and tracheal tension studies. Experimental animals were maintained in a 12:12-h light-dark cycle, pair-fed in accordance with the previous day’s consumption by the nicotine alone-treated group, and allowed free access to water. Animals were killed at postnatal day 21, and their tracheas and lungs were collected for tracheal tension studies, Western blot analysis, and immunofluorescence staining. In a subset of animals at postnatal days 18–21, pulmonary function was evaluated (see below). All animal procedures were performed following National Institutes of Health guidelines for the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committees at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and the University of California Davis.

Pulmonary function testing. Pulmonary function was measured using a plethysmograph for restrained animals (Buxco, Troy, NY), with the rat in the supine position. Dynamic compliance and resistance of the respiratory system were simultaneously measured on the anesthetized, tracheoilluminized, and ventilated rats at baseline and immediately following serial 3-min nebulizations of saline and methacholine (MCh, 0.5 and 2.0 mg/ml), with 3-min recovery periods allowed after each exposure to MCh, as previously described (22, 54). The pups were deeply anesthetized and sedated with medetomidine (0.5 mg/kg; Domitor, Orion Pharma) and tiletamine-zolazepam (50 mg/kg; Telazol, Fort Dodge Laboratories, Overland Park, KS) and then ventilated at 7–8 ml/kg with a small animal ventilator (MiniVent, Harvard Apparatus, Cambridge, MA) for the duration of the procedure.

Address for reprint requests and other correspondence: V. K. Rehan, Dept. of Pediatrics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, David Geffen School of Medicine at UCLA, 1124 West Carson St., Torrance, CA 90502 (e-mail: vrehan@labiomed.org).
**Tracheal tension studies.** The whole trachea was excised immediately after death and dissected free of connective tissue in ice-cold modified Krebs-Ringer bicarbonate buffer (in mM: 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, and 11.1 glucose). Subsequently, a 6-mm tracheal ring was resected from the middle of the trachea and used for tracheal tension studies. The tracheal ring was suspended in an organ chamber filled with 10 ml of modified Krebs-Ringer bicarbonate solution maintained at 37 ± 0.5°C and aerated with 95% O2-5% CO2 (pH 7.4). Each ring was suspended via two stirrups that were passed through the lumen: one stirrup was anchored to the bottom of the organ chamber, and the other stirrup was connected to a strain gauge (model FT03C, Grass Instrument, Quincy, MA) for the measurement of isometric force, as described previously (12).

At the beginning of the experiment, each tracheal ring was stretched to its optimal resting tension, which was achieved by step-wise stretching in 0.1-g increments, until the contractile response to 100 mM KCl reached a plateau. The optimal resting tension was measured, and then each tracheal ring was allowed to equilibrate for 1 h after it was brought to its optimal resting tension. The effects of ACh were determined ≥30 min after the administration of nitro-l-arginine (1 × 10−4 M, an inhibitor of nitric oxide synthase). In all experiments, indomethacin (1 × 10−7 M) was added to the bath to prevent the possible interference by prostanoids.

**Lung morphometry.** Lung morphometry was determined from radial alveolar counts and septal thickness, as described previously (7, 23).

**Immunoblot analysis.** The isolated tracheas and lungs were flash-frozen in liquid nitrogen and then homogenized and sonicated in four volumes of ice-cold lysis buffer containing 50 mM β-glycerophosphate (pH 7.4), 150 mM NaCl, 1.5 mM EDTA, 1 mM diethiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidin, 10 μg/ml leupeptin, 10 μg/ml aprotinin, and 2 μg/ml pepstatin A. After centrifugation at 13,200 g for 15 min at 4°C, the supernatant was used for Western blot analysis for fibronectin, α-smooth muscle actin (α-SMA), calponin, collagen I, and collage III protein expression. The protein concentrations of the supernatant were measured by the Bradford method, with bovine serum albumin as the standard. Aliquots of the supernatant, each containing 30 μg of protein, were separated by SDS-PAGE and electrically transferred to nitrocellulose membranes. Nonspecific binding sites were blocked with Tris-buffered saline (TBS) containing 5% nonfat powdered milk (wt/vol) for 1 h at room temperature. After a brief rinse with TBS containing 0.1% Tween 20 (TBST), the protein blots were incubated in 1:250 diluted anti-fibronectin monoclonal antibody (catalog no. 610078, BD Biosciences), 1:10,000 diluted anti-α-SMA monoclonal antibody (catalog no. A2547, Sigma), 1:6,000 diluted anti-calponin monoclonal antibody (catalog no. C-2687, Sigma), and 1:500 diluted anti-collagen I polyclonal antibody (catalog no. C-2687, Sigma), and 1:20,000 diluted anti-nicotinic AChR monoclonal antibody (catalog no. C7805, Sigma), at 4°C overnight; then Alexa Fluor 488 (1:500 dilution for fibronectin and 1:250 dilution for collagen III) or Alexa Fluor 594 (1:250 dilution for α-SMA and 1:250 dilution for collagen I) goat anti-mouse IgG (Invitrogen) was applied to the sections for 1 h at room temperature. The sections were washed with phosphate-buffered saline and then mounted with ProLong Gold antifade reagent with 4’,6-diamidino-2-phenylindole (Invitrogen) for visualization under a fluorescence microscope.

**Statistics.** Values are means ± SE. Comparisons between the different groups were performed using Student’s t-test or a mixed-model repeated-measures ANOVA with unstructured covariance. P < 0.05 was considered statistically significant.
RESULTS

Initially, we examined the effect of the PPARγ agonist RGZ on nicotine-induced alterations in the resistance of the respiratory system at baseline and following MCh challenge. Nicotine administration significantly increased total resistance, at baseline and following MCh challenge, compared with the control group; concomitant RGZ administration blocked total resistance (P < 0.05), such that pulmonary resistance at baseline and following MCh challenge was similar in the control and nicotine + RGZ groups (Fig. 1A). Accompanying the increase in total resistance, there was a significant decrease in total compliance at baseline and following MCh challenge in the nicotine group that was also blocked by RGZ administration (Fig. 1B).

We then determined tracheal morphometry and the tracheal constriction response to an ACh challenge in the various experimental groups. There were no differences in the tracheal ring outside diameter [2.13 ± 0.06 (n = 16), 2.27 ± 0.10 (n = 16), and 2.12 ± 0.10 mm (n = 13)], length [6.34 ± 0.10 (n = 16), 6.54 ± 0.08 (n = 16), and 6.29 ± 0.13 mm (n = 13)], and optimal resting tension [0.54 ± 0.02 (n = 16), 0.53 ± 0.03 (n = 16), and 0.57 ± 0.03 g (n = 13)] for the control, nicotine, and nicotine + RGZ groups, respectively (P > 0.05). The pattern of tracheal constriction to ACh doses was compared among the three groups using a mixed-model repeated-measures ANOVA with unstructured covariance that accounts for the increasing variability in constriction among animals within groups as the dose increases. The overall dose-response pattern differed among the three groups (P = 0.01), with the nicotine group values significantly (P < 0.05) greater than the control group values at all doses except −log 8 and 7.5 and significantly (P < 0.05) greater than nicotine + RGZ group values at −log doses 7, 6.5, 6, and 5.5. The control group values did not differ (P > 0.05) from the nicotine + RGZ group values at any dose. These results demonstrate that the tracheal constriction response to ACh was significantly increased in the nicotine group and was almost completely blocked in the nicotine + RGZ group (Fig. 2).

Consistent with previous observations, the radial alveolar count was decreased and the septal thickness increased in the nicotine group, and both of these changes were blocked in the nicotine + RGZ group (Fig. 3); alveolar count was 89.1 ± 4.63 ± 0.2, and 87.7 ± 0.3 (SE) alveoli per measured grid (grid size = 0.099 mm²) in control, nicotine, and nicotine + RGZ groups, respectively (Fig. 3B), and septal thickness was 4.46 ± 0.086, 6.01 ± 0.091, and 4.86 ± 0.051 (SE) μm in control, nicotine, and nicotine + RGZ groups, respectively (Fig. 3C).

To determine the effect of perinatal nicotine exposure on mesenchymal markers of airway contractility, we next examined the protein levels of fibronectin, α-SMA, calponin, and collagens I and III in the lung and trachea. The levels of all these proteins increased significantly in the lung and trachea (Figs. 4 and 5). In accordance with the pulmonary function and
tracheal constriction data, all these changes were largely blocked by concomitant RGZ administration. This finding was corroborated by immunofluorescence staining for the mesenchymal markers of airway reactivity in paraformaldehyde-fixed, paraffin-embedded lung sections (Fig. 6). Staining for fibronectin (Fig. 6A), α-SMA (Fig. 6B), calponin (Fig. 6C), and collagen III (Fig. 6D) was increased significantly in the nicotine group compared with the control group and was blocked in the nicotine + RGZ group.

Since we previously determined that, at least under in vitro conditions, the nicotine-induced increase in the alveolar myogenic phenotype is mediated by the nicotinic AChR α3 and -α7 (24, 36), we next determined the levels of these receptors in the lung and trachea. The levels of these receptors increased in the lungs and tracheas of the nicotine-treated animals (Fig. 7). Once again, consistent with the other data in this study, upregulation of the nicotinic AChRα3 and -α7 was blocked by RGZ.

DISCUSSION

It is well established that perinatal exposure to tobacco smoke profoundly affects offspring lung development, predisposing them to later asthma and increased hospital visits and admissions due to respiratory problems (6, 9, 14, 15, 17, 18, 21, 30, 45). Consistent with this knowledge, we found evidence of a significant increase in total pulmonary resistance and a decrease in total compliance under basal conditions with perinatal nicotine exposure compared with the control group. With MCh challenge, compliance decreased further significantly, and resistance increased significantly, all changes consistent with airway hyperresponsiveness following perinatal nicotine exposure.
exposure. Concomitant treatment with RGZ blocked nicotine-induced alterations in pulmonary compliance and resistance under basal conditions and following MCh challenge. Furthermore, perinatal nicotine exposure significantly increased expression of mesenchymal markers of airway reactivity in the trachea and lung parenchyma; expression of these markers was also blocked by the concomitant administration of RGZ. These data lead us to suggest that PPARγ agonists are a promising intervention to prevent tobacco smoke-induced asthma in offspring.

Since prenatal exposure to tobacco smoke has been shown to be more important than postnatal exposure in causing airway hyperresponsiveness in offspring (47), by exposing animals to nicotine throughout lung development, we maximized the likelihood of detecting any differences between the treatment groups. Our results are similar to those of Joad et al. (19), who demonstrated marked increases in airway sensitivity in rats exposed to sidestream smoke during the in utero and postnatal periods, in contrast to animals that had been exposed to sidestream smoke only during the prenatal period or only during the postnatal period. However, in these studies, the molecular markers of airway responsiveness and specific tracheal contractility responses were not determined. Furthermore, no intervention was examined. The present data and our previous studies expand on the findings of Joad et al. and suggest that the underlying molecular pathways involved in linking perinatal nicotine exposure to childhood asthma include enhanced expression of the myogenic pathways, i.e., activation of Wnt signaling and downregulation of PPARγ signaling (23, 34–37, 40, 48). It is important to note that

Fig. 6. Effect of RGZ on perinatal nicotine exposure-induced alterations in mesenchymal markers of airway reactivity in paraformaldehyde-fixed paraffin-embedded lung sections. Nicotine administration significantly increased staining for fibronectin (red, A), α-SMA (green, B), calponin (green, C), and collagen III (red, D) compared with control; these markers were blocked in the RGZ-treated group. Magnification ×400.
Although some of the effects of maternal smoking on the developing lung have been suggested to be stress-induced, the direct effects of maternal smoke on prenatal lung growth are only due to those components of maternal smoke that are transferred across the placenta. There are many agents in smoke that may be detrimental to the developing lung, but there is plenty of evidence to support direct alteration of fetal lung development by nicotine. Nicotine crosses the human placenta with minimal biotransformation, and it accumulates in fetal blood, maternal milk, and amniotic fluid, despite increased nicotine clearance during pregnancy, resulting in exposure of the fetus to even higher levels than the smoking mother.

Nicotine accumulates in several fetal tissues, including the respiratory tract, suggesting that nicotine is the likely agent that alters lung development in the fetus of the pregnant smoker. This is also supported by our in vitro and in vivo studies and studies of others that show direct effects of nicotine on pulmonary epithelial cells, fibroblasts, and the whole lung. Therefore, although we did not expose animals to cigarette smoke as such, there is plenty of evidence to support direct alteration of fetal lung development by nicotine. Nicotine crosses the human placenta with minimal biotransformation, and it accumulates in fetal blood, maternal milk, and amniotic fluid, despite increased nicotine clearance during pregnancy, resulting in exposure of the fetus to even higher levels than the smoking mother. Nicotine accumulates in several fetal tissues, including the respiratory tract, suggesting that nicotine is the likely agent that alters lung development in the fetus of the pregnant smoker. This is also supported by our in vitro and in vivo studies and studies of others that show direct effects of nicotine on pulmonary epithelial cells, fibroblasts, and the whole lung.

Although some of the effects of maternal smoking on the developing lung have been suggested to be stress-induced, the direct effects of maternal smoke on prenatal lung growth are only due to those components of maternal smoke that are transferred across the placenta. There are many agents in smoke that may be detrimental to the developing lung, but there is plenty of evidence to support direct alteration of fetal lung development by nicotine. Nicotine crosses the human placenta with minimal biotransformation, and it accumulates in fetal blood, maternal milk, and amniotic fluid, despite increased nicotine clearance during pregnancy, resulting in exposure of the fetus to even higher levels than the smoking mother. Nicotine accumulates in several fetal tissues, including the respiratory tract, suggesting that nicotine is the likely agent that alters lung development in the fetus of the pregnant smoker. This is also supported by our in vitro and in vivo studies and studies of others that show direct effects of nicotine on pulmonary epithelial cells, fibroblasts, and the whole lung.

Although some of the effects of maternal smoking on the developing lung have been suggested to be stress-induced, the direct effects of maternal smoke on prenatal lung growth are only due to those components of maternal smoke that are transferred across the placenta. There are many agents in smoke that may be detrimental to the developing lung, but there is plenty of evidence to support direct alteration of fetal lung development by nicotine. Nicotine crosses the human placenta with minimal biotransformation, and it accumulates in fetal blood, maternal milk, and amniotic fluid, despite increased nicotine clearance during pregnancy, resulting in exposure of the fetus to even higher levels than the smoking mother. Nicotine accumulates in several fetal tissues, including the respiratory tract, suggesting that nicotine is the likely agent that alters lung development in the fetus of the pregnant smoker. This is also supported by our in vitro and in vivo studies and studies of others that show direct effects of nicotine on pulmonary epithelial cells, fibroblasts, and the whole lung.
use in human infants. In fact, we have used RGZ only as a proof-of-principle to determine the efficacy of the PPARγ agonist class of drugs to block in utero nicotine-induced damage. Since there are significant cardiovascular risks in adult diabetic patients given RGZ over prolonged periods (33), we strongly recommend detailed safety, pharmacokinetic, and pharmacodynamic studies of this class of drugs before recommending their clinical use in pregnant smokers.

REFERENCES


